HCG delivered revenue of INR 6,951 Mn in Q1 FY27, reflecting ~13% YoY growth
Healthcare Global Enterprises Limited (HCG), India’s largest dedicated cancer private hospital network, under the brand “HCG”, has announced its financial results for the quarter ended 30th June 2026.
Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises Ltd., said, “The strong start to FY27 reflects the resilience of HCG’s integrated oncology model and our unwavering commitment to clinical excellence. Over the years, we have consistently invested in expanding access to advanced cancer care while building an institution that combines cutting-edge technology, world-class medical expertise, and compassionate patient care. As we continue to strengthen our network through strategic capacity expansion and focused investments in innovation, we remain committed to shaping the future of oncology and delivering sustainable long-term value for our patients, clinicians, shareholders, and the communities we serve.”
Commenting on the results, Dr. Manish Mattoo, Executive Director & CEO, HealthCare Global Enterprises Limited (HCG), said, “We have started FY27 on a strong note, with revenue growing 13% year-on-year to ₹6,951 million. Excluding North Bangalore hospital, 16 of our 25 centres recorded their highest-ever quarterly revenues, reflecting broad-based growth across our network and sustained demand for our oncology services.
Our focus on increasing the share of high-complexity oncology care and non-institutional business continues to strengthen the quality of our revenue. Non-institutional revenue grew 17% year-on-year, with its contribution increasing from 67% to 69%, while Adjusted EBITDA, grew 20% to ₹1,339 million, with margins improving to 19.4%.
We are encouraged by the strong response to our new North Bangalore hospital, which is expected to contribute meaningfully as insurance empanelment progress and onboarded doctors ramp up their practices. Looking ahead, we remain committed to strengthening clinical leadership, expanding capacity in high-potential markets, and delivering sustainable, profitable growth while enhancing access to world-class cancer care.”
Consolidated Highlights for the Quarter Ending 30th June, 26:
- HCG delivered revenue of INR 6,951 Mn in Q1 FY27, reflecting ~13% YoY growth. North Bangalore hospital commenced operations in May 26, contributed INR 67 Mn in Q1 FY27
- Revenue growth during the quarter was led by volume growth of 11% YoY. ARPP grew by 2% YoY, an improvement driven by a favourable payor mix was partly offset by changes in case mix, including a lower contribution from high-value, low-margin therapies
- Adjusted EBITDA was INR 1,339 Mn in Q1 FY27, up 20% YoY. EBITDA margins improved to 19.4% in Q1 FY27 compared to 18.2% in Q1 FY26
- International business revenue was INR 208 Mn, grew ~9% YoY in Q1 FY27, driven by stronger patient inflows for radiation oncology and PET cases
- Fertility Business divested in June 26; delivered revenue of INR 169 Mn and EBITDA of INR 23 Mn in Q1 FY27
